<DOC>
	<DOC>NCT01937156</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of SP-01 in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic (ME or HE) multi-day chemotherapy，which will provide scientific and reliable clinical data in the drug registration in China.</brief_summary>
	<brief_title>A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Male or female aged ≥ 18years Histologically and/or cytologically confirmed cancer The physical status score ECOG ≤ 2 Life expectancy of ≥3 months Will receive multiday ME/HE chemotherapy (≥2 days) with the emetogenic potential of level 35 In accordance with the indication of chemotherapy and basic requirements; Peripheral Haematology: Hb ≥ 9.0 g/dL, absolute neutrophil count ≥ 1.5×10e9/L, platelet count ≥ 80×10e9/L Blood biochemistry: Total bilirubin &lt; 1.25×ULN, ALT and AST ≤ 2.5×ULN; if liver metastasis, ALT and AST &lt; 5×ULN, Creatinine ≤ 1×ULN, basic normal serum electrolyte (Na, Ka, Cl, Ca) Other important organs function normally Subjects voluntarily participate and signed the informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>